Comerica Bank Increases Holdings in Harmony Biosciences Holdings, Inc. $HRMY

Comerica Bank increased its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 206.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 36,497 shares of the company’s stock after purchasing an additional 24,573 shares during the quarter. Comerica Bank’s holdings in Harmony Biosciences were worth $1,366,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in HRMY. Amundi grew its position in shares of Harmony Biosciences by 115.6% in the first quarter. Amundi now owns 39,668 shares of the company’s stock valued at $1,229,000 after purchasing an additional 21,266 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Harmony Biosciences by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,651 shares of the company’s stock worth $752,000 after buying an additional 984 shares in the last quarter. Empowered Funds LLC purchased a new position in Harmony Biosciences during the first quarter worth about $2,330,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Harmony Biosciences by 53.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 95,389 shares of the company’s stock worth $3,166,000 after buying an additional 33,058 shares in the last quarter. Finally, Cetera Investment Advisers grew its position in Harmony Biosciences by 9.8% during the second quarter. Cetera Investment Advisers now owns 8,404 shares of the company’s stock worth $266,000 after buying an additional 748 shares in the last quarter. 86.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on HRMY. Needham & Company LLC reduced their target price on Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating for the company in a research report on Wednesday, February 25th. UBS Group reduced their target price on Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. Truist Financial boosted their target price on Harmony Biosciences from $25.00 to $29.00 and gave the stock a “hold” rating in a research report on Friday. Weiss Ratings cut Harmony Biosciences from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th. Finally, Mizuho set a $50.00 price objective on Harmony Biosciences in a report on Thursday, February 19th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $40.89.

Key Stories Impacting Harmony Biosciences

Here are the key news stories impacting Harmony Biosciences this week:

• Positive Sentiment: Harmony Biosciences reaffirmed 2026 net revenue guidance of over $1 billion and said demand for WAKIX remained strong, which helps support the long-term outlook. Business Wire article
• Positive Sentiment: H.C. Wainwright reiterated a Buy rating and a $55 price target, citing positive discussions with senior management and reinforcing bullish sentiment on the stock. InsiderMonkey article
• Neutral Sentiment: Several articles noted Harmony Biosciences as a small-cap value name with a relatively low forward P/E, which may attract value investors but does not directly change the near-term earnings picture. InsiderMonkey article
• Neutral Sentiment: Truist raised its price target to $29 from $25 but kept a Hold rating, suggesting only limited upside from current levels. Tickerreport article
• Negative Sentiment: Q1 earnings of $0.55 per share missed estimates of $0.76, and revenue of $215.4 million also came in below expectations, which is the main reason shares are under pressure today. Zacks article
• Negative Sentiment: Management said Q1 market access headwinds were more pronounced this year, which may raise investor concerns about near-term execution even with strong year-over-year revenue growth. Business Wire article

Harmony Biosciences Trading Down 1.4%

HRMY opened at $30.99 on Friday. The business has a 50 day simple moving average of $29.01 and a two-hundred day simple moving average of $33.04. The firm has a market capitalization of $1.79 billion, a price-to-earnings ratio of 12.50, a PEG ratio of 0.43 and a beta of 0.97. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.58 and a quick ratio of 3.58. Harmony Biosciences Holdings, Inc. has a one year low of $25.52 and a one year high of $40.87.

Harmony Biosciences (NASDAQ:HRMY) last released its earnings results on Thursday, May 7th. The company reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.21). The firm had revenue of $215.39 million during the quarter, compared to analysts’ expectations of $220.84 million. Harmony Biosciences had a net margin of 16.20% and a return on equity of 17.19%. The company’s revenue for the quarter was up 16.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.78 EPS. Analysts predict that Harmony Biosciences Holdings, Inc. will post 3.29 EPS for the current year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.